References
- Esposito S, Tagliabue C, Bosis S, et al. Hexavalent vaccines for immunization in paediatric age. Clin Microbiol Infect. 2014;20(Suppl 5):76–85.
- Zepp F, Schmitt HJ, Cleerbout J, et al., Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8(6): 663–678.
- European Medicines Agency. Infanrix hexa product information. [Cited 2018 Oct 16]. Available from: https://www.ema.europa.eu/documents/product-information/infanrix-hexa-epar-product-information_en.pdf
- Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14(3):196–198.
- Rennels MB, Deloria MA, Pichichero ME, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics. 2000;105(1):e12.
- Scheifele DW, Halperin SA, Ferguson AC. Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine. 2001;19(32):4720–4726.
- Woo EJ, Burwen DR, Gatumu SN, et al. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clin Infect Dis. 2003;37(3):351–358.
- Baldo V, Bonanni P, Castro M, et al., Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine; Infanrix hexa: twelve years of experience in Italy. Hum Vaccin Immunother. 2014;10(1): 129–137.
- Bonanni P, Ferro A, Guerra R, et al. Vaccine coverage in Italy and assessment of the 2012–2014 national immunization prevention plan. Epidemiol Prev. 2015;39(4 Suppl 1):146–158.
- Paradowska-Stankiewicz I, Rudowska J. Pertussis in Poland in 2012. Przegl Epidemiol. 2014;68(2):205–207, 325–207.
- European Centre for Disease Prevention and Control. Pertussis. ECDC. Annual Epidemiological Report for 2016. [Cited 2019 Dec 4]. Available from: https://www.ecdc.europa.eu/sites/portal/files/documents/AER-for-2016-pertussis.pdf
- European Medicines Agency. Infanrix hexa: procedural steps taken and scientific information after the authorisation. [Cited 2019 Nov 19]. Available from: https://www.ema.europa.eu/en/documents/procedural-steps-after/infanrix-hexa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
- European Medicines Agency. Prevenar 13 product information. [Cited 2019 July 1]. Available from: https://www.ema.europa.eu/en/documents/product-information/prevenar-13-epar-product-information_en.pdf
- Jorch G, Tapiainen T, Bonhoeffer J, et al. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5707–5716.
- Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25(2):215–222.
- The Information System of the Federal Health Monitoring. Data from germany data sources of the federal statistical office. Statistics on the causes of death. Infant deaths (from 1998). [Cited Nov 2017]. Available from: http://www.gbe-bund.de/gbe10/pkg_isgbe5.prc_isgbe?p_uid=&p_aid=&p_sprache=E
- Centraal Bureau voor de Statistiek (CBS). Central bureau of statistics website. Themes. Health and welfare. Figures. Deaths by main primary cause of death & themes. [Cited Nov 2017]. Available from: https://www.cbs.nl/en-gb/society/health-and-welfare
- Institut National de la Santé et de la Recherche Médicale (INSERM). Centre d’Epidemiologie sur les causes Médicales de décès (CépiDc) - causes médicales de décès. [Cited Nov 2017]. Available from: http://www.cepidc.inserm.fr/
- Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136(2):121–135.
- European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC). Good practice guide on recording, coding, reporting and assessment of medication errors (EMA/762563/2014). [Cited 2019 Nov 19]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/good-practice-guide-recording-coding-reporting-assessment-medication-errors_en.pdf
- Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–44.
- Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
- European Medicines Agency. ICH guideline E2C (R2) on periodic benefit-risk evaluation report (PBRER). [Cited 2019 Oct 18]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-0.pdf
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al. Providing postmarketing periodic safety reports in the ICH E2C(R2) format (Periodic benefit-risk evaluation report): guidance for industry. [Cited 2019 Oct 18]. Available from: https://www.fda.gov/media/85520/download
- Brotherton JM, Hull BP, Hayen A, et al. Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia. Pediatrics. 2005;115(6):e643–646.
- Moro PL, Arana J, Cano M, et al. Deaths reported to the vaccine adverse event reporting system, United States, 1997–2013. Clin Infect Dis. 2015;61(6):980–987.
- Huang WT, Chen RT, Hsu YC, et al., Vaccination and unexplained sudden death risk in Taiwanese infants. Pharmacoepidemiol Drug Saf. 2017;26(1): 17–25.
- Institute of Medicine (US) Immunization Safety Review Committee. Immunization safety review: vaccinations and sudden unexpected death in infancy. Stratton, K, Almario, DA, Wizemann, TM, McCormick, MC (edited by). Washington (DC): The National Academy of Sciences; 2003.
- Moro PL, Perez-Vilar S, Lewis P, et al. Safety surveillance of diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccines. Pediatrics. 2018;142:1.
- Muller-Nordhorn J, Hettler-Chen CM, Keil T, et al. Association between sudden infant death syndrome and diphtheria-tetanus-pertussis immunisation: an ecological study. BMC Pediatr. 2015;15:1.
- Vennemann MM, Butterfass-Bahloul T, Jorch G, et al. Sudden infant death syndrome: no increased risk after immunisation. Vaccine. 2007;25(2):336–340.
- von Kries R. Comment on B. Zinka et al., Unexplained cases of sudden infant death shortly after hexavalent vaccination. Vaccine. 2006;24(31–32):5783–5784; author reply 5785–5786
- von Kries R, Toschke AM, Strassburger K, et al. Sudden and unexpected deaths after the administration of hexavalent vaccines (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b): is there a signal? Eur J Pediatr. 2005;164(2):61–69.
- World Health Organization. Global vaccine safety: six common misconceptions about immunization. [Cited 2019 Dec 4]. Available from: https://www.who.int/vaccine_safety/initiative/detection/immunization_misconceptions/en/index4.html
- Centers for Disease Control and Prevention. Vaccines and sudden infant death syndrome (SIDS). [Cited 2019 Dec 4]. Available from: https://www.cdc.gov/vaccinesafety/concerns/sids.html#rel
- European Medicines Agency. EMA public statement: EMA update on hexavalent vaccines: hexavac and Infanrix hexa. [Cited 2018 Oct 18]. Available from: https://www.ema.europa.eu/en/documents/public-statement/european-medicines-agency-public-statement-update-hexavalent-vaccines-hexavac-infanrix-hexa_en.pdf
- Moon RY, Fu L. Sudden infant death syndrome: an update. Pediatr Rev. 2012;33(7):314–320.
- Carlin RF, Moon RY. Risk factors, protective factors, and current recommendations to reduce sudden infant death syndrome: a review. JAMA Pediatr. 2017;171(2):175–180.
- Vennemann MM, Findeisen M, Butterfass-Bahloul T, et al. Modifiable risk factors for SIDS in Germany: results of GeSID. Acta Paediatr. 2005;94(6):655–660.
- Wang S, Tafalla M, Hanssens L, et al. A review of Haemophilus influenzae disease in Europe from 2000–2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16(11):1095–1105.
- Di Pasquale A, Bonanni P, Garcon N, et al., Vaccine safety evaluation: practical aspects in assessing benefits and risks. Vaccine. 2016;34(52): 6672–6680.
- Edwards KM, Hackell JM. Countering vaccine hesitancy. Pediatrics. 2016;138:3.
- Gidengil C, Chen C, Parker AM, et al. Beliefs around childhood vaccines in the United States: a systematic review. Vaccine. 2019;37(45):6793–6802.
- Larson HJ, Jarrett C, Eckersberger E, et al. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007–2012. Vaccine. 2014;32(19):2150–2159.
- McClure CC, Cataldi JR, O’Leary ST. Vaccine hesitancy: where we are and where we are going. Clin Ther. 2017;39(8):1550–1562.
- Clarke KEN, MacNeil A, Hadler S, et al. Global epidemiology of diphtheria, 2000–2017(1). Emerg Infect Dis. 2019;25(10):1834–1842.
- World Health Organization. Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec. 2017;92(6):53–76.